-

04:57:37 AM

AEZS Stock News

AEZS - Aeterna Zentaris Inc.

05/18/22 8:00 AM

Nasdaq : AEZS

conferences

Aeterna Zentaris to Present at the H.C. Wainwright Global Investment Conference

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that Dr. Klaus

RHEA-AI

neutral

05/16/22 8:00 AM

Nasdaq : AEZS

Aeterna Zentaris Announces Virtual 2022 Meeting of Shareholders and Urges Shareholders to Vote in Favor of the Proposed Share Consolidation

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“ Aeterna ” or the “ Company ”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that its Virtual Annual General and Special

RHEA-AI

neutral

05/12/22 8:05 AM

Nasdaq : AEZS

clinical trial

Update on Positive Pre-Clinical Results from AIM Biologicals Development Program for the Potential Treatment of Parkinson’s Disease

– Data presented at IMMUNOLOGY2022 ™ , the A nnual Event of the American Association of Immunologists – Company advancing development of its Autoimmunity Modifying ( “ AIM ” ) Biologic al s as a potential therapeutic treatment option for Parkinson’s Disease (" PD ") TORONTO, ONTARIO, May 12, 2022

RHEA-AI

positive

05/11/22 8:05 AM

Nasdaq : AEZS

earnings

Aeterna Zentaris Reports First Quarter 2022 Financial Results and Provides Business Outlook

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”),

RHEA-AI

neutral

04/25/22 8:05 AM

Nasdaq : AEZS

Aeterna Zentaris Abstract Accepted for Presentation at IMMUNOLOGY2022™, the Annual Event of the American Association of Immunologists

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS)

RHEA-AI

neutral

04/19/22 8:05 AM

Nasdaq : AEZS

Aeterna Zentaris Secures New European Patent Related to Use of Macimorelin for the Diagnosis of Growth Hormone Deficiency in Adults

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or

RHEA-AI

neutral

04/13/22 10:45 AM

Nasdaq : AEZS, CNSP, AREC

JTC Team Announces Continuation of its Virtual Investor Spotlight Series with NASDAQ: AEZS, NASDAQ: CNSP, and NASDAQ: AREC

JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced the continuation of its Virtual Investor Spotlight

RHEA-AI

neutral

04/12/22 8:05 AM

Nasdaq : AEZS

conferences

Aeterna Zentaris to Participate at the Virtual Investor 2022 CEO Spotlight

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a

RHEA-AI

neutral

04/11/22 8:05 AM

Nasdaq : AEZS

Aeterna Zentaris Abstract Accepted for Presentation at 13th International Congress on Autoimmunity

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX:

RHEA-AI

neutral

03/29/22 8:00 AM

Nasdaq : AEZS

earnings

Aeterna Zentaris Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Outlook

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS)

RHEA-AI

neutral

AEZS Data

IndustryBiological Product (except Diagnostic) Manufacturing
Websitewww.aezsinc.com
CeoKlaus Paulini
Security nameAeterna Zentaris Inc.
Issue typecs
SectorManufacturing
Sic code2834
Employees11
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Biological Product (except Diagnostic) Manufacturing
Address315 Sigma Drive
StateSouth Carolina
CitySummerville
Zip29486
CountryUnited States
Phone18439003223

About Aeterna Zentaris Inc.

Aeterna Zentaris Inc. is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The Company's lead product, macimorelin, is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). Macimorelin is currently marketed in the United States under the tradename Macrilen™through a license agreement with Novo Nordisk where Aeterna Zentaris receives royalties on sales. According to a commercialization and supply agreement, MegaPharm Ltd. will seek regulatory approval and then commercialize macimorelin in Israel and the Palestinian Authority. Additionally, upon receipt of pricing and reimbursement approvals, Aeterna expects that macimorelin will be marketed in Europe and the United Kingdom through a recently established license agreement with Consilient Health Ltd and Aeterna Zentaris will receive royalties on sales and other potential payments.